-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
-
-
-
-
-
-
-
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
-
-
-
-
-
-
15,740 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

